The following trials are fully managed:
Title: Randomised, Phase II open label study of Rituximab/Ibritinib vs Rituximab/Chemo in older patients with mantle cell lymphoma.
Title: A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma.
Chief Investigator: Professor Steven Le Gouill (Institut Curie - Paris)
Associate Coordinating Investigator: Dr David Lewis (UHPNT)
Title: Simvastatin as a neuroprotective treatment for Parkinson’s disease – a double-blind, placebo controlled clinical learning study in patients of moderate severity.
Chief Investigator: Dr Camille Carroll, Faculty of Medicine and Dentistry, University of Plymouth.
Title: A pilot multi-centre three arm randomised controlled feasibility study (for a definitive trial) of the clinical and cost-effectiveness of facet joint injections in patients with persistent non-specific low back pain of more than six months' duration.
Chief Investigator: Professor Richard Langford, Bath and The London NHS Trust